Page 5 - Anjali Singh

Pharma stocks rise as US considers exempting generics from tariffs

Among major gainers, Aurobindo Pharma led the rally, surging 4.49 per cent to Rs 1,118.9, followed by Lupin, which climbed 2.73 per cent to Rs 1,957.6

AHPI, insurers discuss common empanelment and faster claims for patients

The meeting between AHPI and insurers focused on a unified hospital empanelment system, quicker claim settlements, and improved patient experience nationwide

India could gain ₹3.6 trillion annually from better eye health: Report

A global study says basic eye care like screenings and glasses can yield ₹16 for every ₹1 spent, boosting India's productivity and education outcomes

Hospital fires expose deep safety lapses, weak enforcement across India

While such practices exist in leading private facilities, experts say public hospitals, often stretched and underfunded, struggle with outdated wiring, inadequate maintenance, and lax inspection

Maharashtra to become India's semiconductor capital by 2030: Dhavse

"The next decade will be defined by chips, and India will be at the centre of this transformation," Dhavse said

M&M cuts Bolero prices below ₹10 lakh, ramps up production capacity

The move comes as the entry-level SUV market grows increasingly competitive, with players aggressively vying for market share

Indian pharma market grows 7.3% in September, chronic drugs gain traction

India's pharmaceutical market rose 7.3% year-on-year in September to ₹20,886 crore, driven by robust growth in antidiabetic, cardiac, and respiratory therapies

Genomic testing gets affordable, drives expansion beyond metro cities

Once niche and costly, genomic testing is becoming affordable across India as prices fall 30-40 per cent, with hospitals and diagnostic chains expanding into Tier-2 and Tier-3 cities

Fewer variants, lower prices: Tata Motors reworks Harrier, Safari strategy

Company executives added that the Adventure X trims are expected to lift sales volumes, though average selling prices may soften compared with last year, when demand was led by high-end variants

Tata Motors announces leadership transition amid demerger plans

Tata Motors announced major leadership changes as it prepares to demerge its commercial vehicle business into TML Commercial Vehicles Ltd, effective October 1, 2025

Indian pharma sector revenue growth to ease to 7-9% in FY26: Crisil

Crisil projects India pharma growth at 7-9% in FY26 as exports to regulated markets slow after a US high base while domestic sales benefit from tax cuts and launches

7 out of 10 digital projects in India's pharma sector fail: Vector study

Vector Consulting Group study finds pharma firms spend up to ₹75 cr annually on IT systems, but 70% of digital projects fail due to adoption gaps and poor execution

Apollo Hospitals expands genomics network, targets affordable testing

Apollo Hospitals to expand genomics institutes to Tier-2 cities including Guwahati, Bhubaneswar and Indore, aiming to cut test costs and boost access beyond metro regions

GST reforms: New regime, but old problems persist for car dealers

With new GST rates kicking in, auto dealers face uncertainty on recovering compensation cess from unsold stock, even as OEMs cut prices to spur festive demand

Zelio E-Mobility to raise ₹78 crore via SME IPO for R&D, expansion

Hisar-based Zelio E-Mobility to raise Rs 78 crore through an SME IPO to fund new plants, strengthen R&D, reduce debt and enhance capacity to meet growing demand for EVs

HNIs doubled in just 4 years, fuelling surge in luxury auto demand

India's millionaire households have nearly doubled to 8.7 lakh in four years, creating a runway for luxury car demand as wealth fuels aspirations and premium consumption

Lupin gets USFDA nod for generic cancer drug Lenalidomide capsules

Lupin has received USFDA approval for generic Lenalidomide capsules in six strengths, adding to competition in the US oncology market for Bristol-Myers Squibb's Revlimid

Spinny cuts used car prices ahead of GST change, up to ₹2 lakh off

Spinny has reduced used car prices ahead of GST reforms from September 22, offering buyers up to Rs 2 lakh savings and sellers up to Rs 20,000 higher resale benefit

Hospitals vs insurers: Policyholders bear the brunt of rising medical costs

The simmering conflict came to a head last month when Niva Bupa suspended cashless services at Max Hospitals on August 16, citing unresolved reimbursement issues

Novartis' Vymada patent revoked, generics set to slash prices by 70%

Novartis lost its Vymada patent in India, enabling generic drugmakers to launch versions that could slash prices by up to 70 per cent and improve access for cardiac patients